Mizuho target puts Lantheus Holdings stock 8.58 percent below USD 109.00
Published on 10/20/2026 at 22:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst and operating figures
- Mizuho reaffirmed a Neutral rating and cut its Lantheus target from USD 115.00 to USD 109.00 on October 13, 2026.
- Lantheus reported USD 388.18 million in second-quarter revenue, up 2.70 percent year over year.
- Lantheus Holdings stock costs EUR 89.30 at Lang & Schwarz on October 20, 2026 at 10:00 p.m. CEST.
- The company had a USD 6.6 billion market capitalization and a 24.25 price-to-earnings ratio as of October 20, 2026.
Mizuho reaffirmed its Neutral rating on Lantheus and lowered its price target from USD 115.00 to USD 109.00 in a research report dated October 13, 2026, as MarketBeat reported. The revised target is 8.58 percent above the USD 100.39 Nasdaq price at the October 20, 2026 after-hours timestamp. Lantheus stock was trading at EUR 89.30 at Lang & Schwarz on October 20, 2026 at 10:00 p.m. CEST.
Revenue reaches USD 388.18 million
Lantheus generated USD 388.18 million in the second quarter ended June 30, 2026, according to MarketBeat. Revenue increased 2.70 percent from the same period a year earlier, while reported earnings per share reached USD 1.55 against a USD 1.30 consensus estimate. The comparison gives the analyst target a concrete operating backdrop rather than leaving it as a standalone valuation call.
Stock remains below its yearly high
The Nasdaq price of USD 100.39 on October 20, 2026 stood USD 11.47 below the 52-week high of USD 111.86 and USD 50.23 above the 52-week low of USD 50.16. Trading volume reached 1,324,180 shares at the same timestamp. The range shows that the current quotation is materially above the yearly low while still below the upper end of its recent trading band.
Valuation reflects a specialized portfolio
Lantheus had a USD 6.6 billion market capitalization and a 24.25 price-to-earnings ratio as of October 20, 2026. Its business covers radiopharmaceutical oncology, precision diagnostics and strategic partnerships, including PYLARIFY and DEFINITY, according to the company profile at Lantheus. The company reported USD 75.03 million of net income and a 26.00 percent operating margin for the second quarter ended June 30, 2026.
The target sets the central valuation marker
Mizuho's USD 109.00 target is 8.58 percent above the USD 100.39 Nasdaq price, while the consensus cited by MarketBeat was a Hold rating and an average target of USD 107.44 on October 13, 2026. That places the Mizuho view USD 1.56 above the reported consensus average. For investors, the key distinction is between the operating figures already reported for the second quarter and the valuation level implied by the analyst target.
Where Lantheus stock stands
The euro quotation was trading at EUR 89.30 at Lang & Schwarz on October 20, 2026 at 10:00 p.m. CEST. The company remains listed on the Nasdaq under ticker LNTH, with the US quotation at USD 100.39 after hours on October 20, 2026.
The further course of trading is shown by the continuously updated real-time quote of Lantheus Holdings stock.
Lantheus Holdings market facts
- Company: Lantheus Holdings, Inc.
- ISIN: US5165441032
- Ticker: LNTH
- Primary exchange: NASDAQ
- Price Lang & Schwarz (as of October 20, 2026, 10:00 p.m. CEST): EUR 89.30
- Market capitalization: USD 6.6 billion (as of October 20, 2026)
- 52-week range: USD 50.16-111.86 (as of October 20, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty & Generic
Market context: Market report Nasdaq Composite.
